SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Cost effectiveness vs. affordability in the age of immuno-oncology cancer drugs
4 references·0 citing·17 second hop
Cost effectiveness vs. affordability in the age of immuno-oncology cancer drugs (2018)Cost effectiveness vs. affordability in t…Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States (2017)Cost Effectiveness of Pembrol…Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma (2017)Cost Effectiveness of Nivolum…Using Effectiveness and Cost-effectiveness to Make Drug Coverage Decisions (2009)Using Effectiveness and Cost-…Methods for the Economic Evaluation of Health Care Programmes (2005)Methods for the Economic Eval…Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysis (2004)Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers (2010)Attributes and weights in health care priority setting: A systematic review of what counts and to what extent (2015)Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries (2017)Modeling Valuations for EuroQol Health States (1997)Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold (2014)Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses (2016)Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US (2018)First‐line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non–small cell lung cancer: A United States–based cost‐effectiveness analysis (2019)Cost-Effectiveness Analysis of Durvalumab Plus Chemotherapy in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (2021)Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study (2015)First- and Second-Line Bevacizumab in Addition to Chemotherapy for Metastatic Colorectal Cancer: A United States–Based Cost-Effectiveness Analysis (2015)Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer (2018)Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China (2019)United States Life Tables, 2017. (2019)The estimation of a preference-based measure of health from the SF-36 (2002)Systematic reviews: CRD's guidance for undertaking reviews in health care (2010)
this work references cited by second hop

References

  • 2005Methods for the Economic Evaluation of Health Care Programmes13,647 cited
  • 2009Using Effectiveness and Cost-effectiveness to Make Drug Coverage Decisions343 cited
  • 2017Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States142 cited
  • 2017Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma66 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work